Q-omics provides the consensus-scored UBE2Q2P6 profile across patient tissues and cancer cell-line models. UBE2Q2P6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UBE2Q2P6 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, UBE2Q2P6 RNA expression shows 13,530 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where UBE2Q2P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2Q2P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2Q2P6 survival associations across molecular data types. UBE2Q2P6 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2Q2P6 RNA expression–survival associations across cancer types. High UBE2Q2P6 expression shows unfavorable associations in KIRC, THCA, COAD, LIHC and LUSC, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UBE2Q2P6 RNA expression.
This table summarizes UBE2Q2P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2Q2P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2Q2P6 shows lower tumor expression in STAD, BRCA, THCA and COAD and higher tumor expression in HNSC and KICH. The HNSC box plot shows higher UBE2Q2P6 RNA expression in tumor versus normal tissue (log2 FC = +0.192, t-test p = .002).
This table shows molecular features associated with UBE2Q2P6 in patient tissues and cancer cell lines. In patient samples, UBE2Q2P6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
